

Real-world evidence data characterizing the use of the monoclonal antibody erenumab in daily clinical routine in Germany from the treating physician's perspective (TELESCOPE)

Andreas Straube¹, Philipp Stude², Charly Gaul³, Katrin Schuh⁴, Mirja Koch⁴
¹ LMU Munich, Germany
² Neurologische Praxis Bochum, Germany
³ Migraine and Headache Clinic, Koenigstein am Taunus, Germany
⁴ Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg

BACKGROUND

- Erenumab is the first-in-class fully human monoclonal antibody targeting the Calcitonin- Gene-Related-Peptide (CGRP) receptor
- In 2018, erenumab was approved by the FDA and EMA for the prophylactic treatment of migraine in adults
- Safety and efficacy of erenumab has been shown in multiple clinical trials

OBJECTIVE

- TELESCOPE collected first real-world data by characterizing the use of erenumab in clinical practice from the treating physicians' perspective in Germany.

METHODS

- Data from 45 headache centers across Germany was collected via an online survey from July- December 2019
- The survey consisted of two parts:
 - Capturing the treating-physician's perspective on erenumab treatment with regards to therapy decision, patient profiles and quality of life of the patients
 - Documentation of treatment effects and satisfaction with outcome of 10-20 individual episodic and chronic migraine patients with at least 3 months of erenumab treatment
- In total, 542 erenumab patients were documented, of which 50% were suffering from episodic and 50% from chronic migraine

DISCLOSURE

Andreas Straube has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Allergoan, Bayer, electroCore, Eli Lilly, Novartis, Sanofi, TEVA. Dr. Straube has received research support from Novartis Pharma, Philipp Stude has received honoraria for consulting, speaking or other activities from Allergan, Eli Lilly, Hormosan, Novartis, TEVA. Charly Gaul has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan Pharma, Ratiopharm, Boehringer Ingelheim Pharma, Lilly, Novartis Pharma, Desitin Arzneimittel, Carbotec, Bayer vital, Hormosan Pharma, electroCore, Reckitt Benckiser, and Teva.
 Mirja Koch and Katrin Schuh are employees at Novartis Pharma GmbH.
 This study was funded by Novartis Pharma GmbH, Nuremberg, Germany.

RESULTS

Figure 1. Physicians' cohort and erenumab patients' profile






Figure 2. Effect of erenumab on migraine specific parameters




• Mean change in monthly migraine days was -6.3 and mean change in acute medication days was -6.4 (n=542)

Figure 3. Onset of response to erenumab treatment




• For 69% of patients, treating physicians already see a response after the first injection (n=45)

Figure 4. Effect of erenumab on migraine characteristics




• 91% of patients show an improvement regarding the clinical global impression scale 3 months after initiation of erenumab therapy (n=494)
 • 85% of patients show improvement in migraine attack frequency (n=542)

Figure 5. Improvements in accompanying symptoms and satisfaction with erenumab



• Erenumab improved migraine-related symptoms in migraine patients (n=542)
 • 80% of patients were satisfied with erenumab treatment (n=542)

Figure 6. Responder rate and responder classification



• 83% of patients were classified as responders according to treating physicians (n=542)
 • 73% of physicians state the reduction of monthly migraine days to be the most important criteria for responder classification (n=45)

CONCLUSION

- TELESCOPE provides us with **real-world evidence data** for erenumab in Germany
- This study captured the effects of erenumab on migraine specific parameters, global impression and impact on migraine-related symptoms **from the treating physicians' perspective**
- In a cohort of randomly selected migraine patients, erenumab significantly reduced monthly headache, monthly migraine and acute medication days
- Based on the assessment of treating physicians, erenumab improved global impression in 91% of their patients
- Erenumab improved migraine-related symptoms and 80% of patients are satisfied with erenumab treatment
- According to treating physicians, 83% of patients responded to erenumab treatment